Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial

Wei Tang, Zhujun Cao, Mingfeng Han, Zhengyan Wang, Junwen Chen, Wenjin Sun, Yaojie Wu, Wei Xiao, Shengyong Liu, Erzhen Chen, Wei Chen, Xiongbiao Wang, Jiuyong Yang, Jun Lin, Qingxia Zhao, Youqin Yan, Zhibin Xie, Dan Li, Yaofeng Yang, Leshan Liu, Jieming Qu, Guang Ning, Guochao Shi, Qing Xie
doi: https://doi.org/10.1101/2020.04.10.20060558

Data Availability

Anonymized datasets can be made available on reasonable request after approval from the trial management committee and after signing a data access agreement. Proposals should be directed to the corresponding author.

Back to top
Posted May 07, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial
Wei Tang, Zhujun Cao, Mingfeng Han, Zhengyan Wang, Junwen Chen, Wenjin Sun, Yaojie Wu, Wei Xiao, Shengyong Liu, Erzhen Chen, Wei Chen, Xiongbiao Wang, Jiuyong Yang, Jun Lin, Qingxia Zhao, Youqin Yan, Zhibin Xie, Dan Li, Yaofeng Yang, Leshan Liu, Jieming Qu, Guang Ning, Guochao Shi, Qing Xie
medRxiv 2020.04.10.20060558; doi: https://doi.org/10.1101/2020.04.10.20060558
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area